Rifampicin

WITHDRAWN · PHASE3 · Tuberculosis Infection

Lack of Rifapentine

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.